NYON, Switzerland, Sept. 25, 2008 (GLOBE NEWSWIRE) -- Mymetics Corporation (OTCBB:MYMX),a vaccine development company, as previously announced on September 23rd 2008, is pleased to announce their preliminary SHIV challenge results on non-human primates previously immunized with the Company’s mucosal HIV-AIDS vaccine designed for triggering mucosal protection. The results significantly exceed the Industry standard of 60% to 70% effectiveness to be considered as a promising vaccine, as well as of Mymetics’ expectation which was considerable above this level. The Company will continue to do further tests to confirm these results and will present all the results at the Keystone Symposia. With the recent public announcements by major HIV opinion leaders and pharmaceutical companies of their disappointing results despite significant investments in non productive vaccine strategies, attention is now beginning to refocus on the mucosa approach. Mymetics, with a robust IP portfolio and having originally decided 5 years ago to develop an HIV vaccine utilizing mucosal antibody protection as the first line of defense, anticipates a fundamental change in the direction of HIV/AIDS research towards the mucosa solution in the near future.
